SBK3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1857854	0.52	2/20
SCHEMBL1855955	0.51	2/20
SCHEMBL1860032	0.51	2/20
SCHEMBL1860908	0.51	2/20
SCHEMBL1858079	0.47	2/20
SCHEMBL1862265	0.47	2/20
SCHEMBL1856316	0.44	2/20
SCHEMBL1865625	0.44	2/20
SCHEMBL1856282	0.44	2/20
SCHEMBL1861344	0.44	2/20
SCHEMBL1858489	0.43	2/20
SCHEMBL1855569	0.43	2/20
SCHEMBL1855396	0.42	2/20
SCHEMBL1859661	0.42	2/20
SCHEMBL1865629	0.41	2/20
Ruxolitinib (SCHEMBL99225)	1.00	1/20
Ruxolitinib (SCHEMBL101279)	1.00	1/20
Ruxolitinib (SCHEMBL171319)	1.00	1/20
SCHEMBL256712	1.00	1/20
SCHEMBL99245	0.98	1/20

Clinical trials — most relevant to SBK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Salt Loading and Thiazide Intervention Study	PHASE4	COMPLETED
Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor	PHASE2	ACTIVE_NOT_RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Study of ASTX029 in Subjects With Advanced Solid Tumors	PHASE1/PHASE2	COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib	EARLY_PHASE1	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study	nan	COMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer	nan	COMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.	nan	UNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders	nan	COMPLETED
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy	nan	COMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SBK3 binder may also engage these)

Protein	Name	Similarity
P0C5K0	—	0.992	P0C5K0 →
B1WBU5	—	0.986	B1WBU5 →
P0C5K1	—	0.984	P0C5K1 →
P0C263	—	0.978	P0C263 →
Q28616	—	0.978	Q28616 →
Q16671	—	0.973	Q16671 →
Q62893	—	0.972	Q62893 →
Q8K592	—	0.971	Q8K592 →
TNK1	Non-receptor tyrosine-protein kinase TNK1	0.971	landscape →
Q99ML2	—	0.968	Q99ML2 →
Q8N398	—	0.968	Q8N398 →
PIM2	Serine/threonine-protein kinase pim-2	0.967	landscape →
Q6ZW31	—	0.965	Q6ZW31 →
Q9D856	—	0.965	Q9D856 →
Q3UR50	—	0.965	Q3UR50 →
Q6ZS72	—	0.965	Q6ZS72 →
P54777	—	0.965	P54777 →
D3KCC4	—	0.965	D3KCC4 →
Q7Z7M1	—	0.964	Q7Z7M1 →
Q99LC9	—	0.964	Q99LC9 →
A7MBM2	—	0.964	A7MBM2 →
Q6F5E8	—	0.964	Q6F5E8 →
Q0VCE3	—	0.964	Q0VCE3 →
Q6ZMH5	—	0.964	Q6ZMH5 →
PKN3	Serine/threonine-protein kinase N3	0.963	landscape →
MAP3K6	Mitogen-activated protein kinase kinase kinase 6	0.963	landscape →
GHDC	GH3 domain-containing protein	0.963	landscape →
Q8NAG6	—	0.963	Q8NAG6 →
Q5TJE4	—	0.963	Q5TJE4 →
Q3UR97	—	0.962	Q3UR97 →